You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What happens to body weight after discontinuation of Foundayo™ (orforglipron) for weight management?
Eli Lilly and Company does not have data on the impact of orforglipron treatment discontinuation on body weight reduction and other efficacy outcomes, as this has not been studied.
See important safety information, including boxed warning, in the attached prescribing information.
Orforglipron Efficacy After Discontinuation
Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and physical activity to reduce excess body weight and maintain weight reduction long term in adults with
- obesity, or
- overweight in the presence of at least one weight-related comorbid condition.1
Eli Lilly and Company does not have data on the impact of orforglipron treatment discontinuation on body weight reduction and other efficacy outcomes, as this has not been studied.
Enclosed Prescribing Information
Reference
1Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: April 06, 2026